Neimeth International Pharmaceuticals Plc emerged as the fastest-growing listed pharmaceutical company by revenue in the first half of 2026, recording a 26 per cent year-on-year increase in sales despite a challenging operating environment marked by high borrowing costs, inflationary pressures and foreign exchange volatility.
An analysis of the unaudited half-year financial statements of three major listed pharmaceutical companies—Neimeth International Pharmaceuticals Plc, Fidson Healthcare Plc and May & Baker Nigeria Plc shows that while Fidson retained its leadership in terms of revenue and profitability, Neimeth delivered the strongest top-line growth among its peers, reflecting improving market penetration and sustained demand for its pharmaceutical products.
Neimeth’s revenue rose to N3.66 billion in the six months ended June 30, 2026, from N2.91 billion recorded in the corresponding period of 2025, representing a 26 per cent increase.
The company’s revenue performance underscores its ability to expand sales despite operating from a significantly smaller asset and production base than its larger competitors. Industry analysts note that faster revenue growth often reflects successful market expansion, stronger product acceptance and effective commercial execution, particularly in a highly competitive pharmaceutical market.
